Dravo Bay’s Prelude Therapeutics PRLD Stock Holding History

Dravo Bay’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-650	Closed	-$4.49K	–	130
2022 Q1	$4.49K	Buy	+650	New	+$5.95K	﹤0.01%	123

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dravo Bay's PRLD Position: Q2 2022 in Review

Dravo Bay sold out of Prelude Therapeutics (PRLD) in Q2 2022, closing a stake of 650 shares — an estimated $4.49K sold.

Dravo Bay first reported a position in PRLD in Q1 2022 and held it in 1 quarter. The position peaked at $4.49K in Q1 2022. 62 funds tracked by Wall St. Rank hold PRLD as of Q2 2022.

Dravo Bay reported no remaining Prelude Therapeutics position as of Q2 2022 after selling out during the quarter.
Dravo Bay sold 650 Prelude Therapeutics shares in Q2 2022, an estimated $4.49K.
Dravo Bay first reported a position in Prelude Therapeutics in Q1 2022 and held it in 1 quarter.
Dravo Bay's Prelude Therapeutics position peaked at $4.49K in Q1 2022.
62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2022.

Based on Dravo Bay's 13F filing for Q2 2022, filed 15 Aug 2022.